Predictions
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€91.50
29.11.23
29.11.23
€123.00
29.11.24
29.11.24
12.37%
04.10.24
04.10.24
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€35.60
29.11.23
29.11.23
-
29.11.24
29.11.24
37.08%
04.10.24
04.10.24
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
28.20%
23.09.24
23.09.24
Jazz Pharmaceuticals plc
Start price
Target price
Perf. (%)
€104.55
29.11.23
29.11.23
€205.00
29.11.24
29.11.24
-4.68%
04.10.24
04.10.24
Verastem Inc.
Start price
Target price
Perf. (%)
€5.80
29.11.23
29.11.23
-
29.11.24
29.11.24
-28.62%
25.05.24
25.05.24
Could be very worthwhile Investment >20% year
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€729.00
28.11.23
28.11.23
€852.48
28.11.24
28.11.24
26.53%
04.10.24
04.10.24
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€729.00
28.11.23
28.11.23
€951.37
28.11.24
28.11.24
26.53%
04.10.24
04.10.24
Inotiv Inc.
Start price
Target price
Perf. (%)
€2.46
28.11.23
28.11.23
€0.000
28.11.24
28.11.24
26.83%
09.12.23
09.12.23
Risky Investment
EBIT decline > 20% expected
Decining EBIT margin than peer group
High valuation
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€2.02
27.11.23
27.11.23
-
27.11.24
27.11.24
77.37%
23.06.24
23.06.24
Risky Investment
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€51.82
27.11.23
27.11.23
-
27.11.24
27.11.24
4.21%
23.01.24
23.01.24
Teva Pharmaceutical Industries Ltd ADR
Start price
Target price
Perf. (%)
€8.94
27.11.23
27.11.23
€11.87
27.11.24
27.11.24
78.41%
04.10.24
04.10.24
Kezar Life Sciences
Start price
Target price
Perf. (%)
€0.80
27.11.23
27.11.23
€18.27
27.11.24
27.11.24
-19.38%
04.10.24
04.10.24
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€1.51
27.11.23
27.11.23
-
27.11.24
27.11.24
4.25%
11.12.23
11.12.23
Probably not worthwhile Investment
Organovo Holdings Inc.
Start price
Target price
Perf. (%)
€1.06
27.11.23
27.11.23
€4.00
27.11.24
27.11.24
-4.33%
09.12.23
09.12.23
Standard Investments for future growth
High valuation
Very low/no dividend yield expected
negative Cash Flow expected